An observational study in Diabetes and Obesity, sponsored by University of Pittsburgh. Completed at 1 site in United States. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2007-12-19.
Sponsored by University of Pittsburgh · Observational
The purpose of this research is to develop a new method to study insulin action using positron emission tomography (PET). Insulin is the hormone made by your body to control the blood sugar level. We want to develop a way to image (look at) the following three things: 1) how insulin affects blood flow in skeletal muscle 2) how insulin affects glucose (sugar) transport (movement) into muscle, and 3) how insulin affects glucose metabolism (breakdown) in skeletal muscle of healthy individuals. The long term goal will be to later apply this method to the study of metabolic diseases, especially type 2 diabetes mellitus and obesity.
PET imaging is a relatively non-invasive way to obtain a "metabolic picture" of body organs, and has been used successfully to study brain, heart and more recently skeletal muscle. In this research study, we will use PET with as many as four radioactive tracers (markers) to study skeletal muscle glucose transport in healthy volunteers.
The goal of this proposal is to develop a novel triple-tracer positron emission tomography (PET) method to image in vivo insulin-stimulated tissue perfusion, glucose transport and glucose phosphorylation in skeletal muscle in healthy individuals. The long term goal will be to later apply this model to the study of metabolic diseases, notably type 2 diabetes mellitus (Type 2 DM) and obesity (Ob). While it is often suggested that glucose transport is the rate-controlling step for insulin action, we will test the hypothesis that the control insulin exerts on the uptake of glucose into skeletal muscle is distributed across flow and tissue perfusion, trans-membrane transport and intra-cellular phosphorylation of glucose.
Specific Aim 1. The first specific aim is to develop the triple-tracer PET method for quantitative determinations of tissue perfusion, glucose transport and glucose phosphorylation in skeletal muscle. To measure blood flow and tissue perfusion, we will use 15O-H2O (half-life \~ 2 min; also referred to as 15O-water). To measure glucose transport, we will use 11C-3-O-methyl glucose (half-life \~ 20 min; also referred to as 3-0-MG), an analog that is transported but not phosphorylated or otherwise metabolized. 18F-2-deoxy-2-fluoro-glucose (half-life \~ 109 min; also referred to as FDG), will be used to examine glucose transport and glucose phosphorylation. Because of the differences in half-life of the three positrons (15O, 11C, and 18F), it is feasible to use each of these tracers, in sequence, in the same individual.
Specific Aim 2. The second specific aim is to rigorously test mathematical models to extract quantitative physiological information from dynamic PET imaging. We will test a novel model that specifically addresses the kinetics of substrate delivery within the interstitial space of skeletal muscle (i.e. a 5 rate constant, 4 compartment model with respect to FDG. Model testing will entail use of non-compartmental models e.g. spectral analysis).
11,089 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's enrollment of 50 is below the median of 234 across 2,254 observational studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →University of Pittsburgh is the lead sponsor of 1,414 studies on the registry; 168 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Triple tracer PET method development for in vivo imaging of skeletal muscle metabolism
Testing of mathematical modeling of PET data
This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.